The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.
 
Reem Karmali
Honoraria - Bio Ascend; Prime Oncology
Consulting or Advisory Role - Juno Therapeutics; Karyopharm Therapeutics; Kite/Gilead
Speakers' Bureau - AstraZeneca; BeiGene; Kite/Gilead
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Juno Therapeutics (Inst); MedImmune (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Prime Oncology
 
Jeffrey M. Switchenko
No Relationships to Disclose
 
Subir Goyal
No Relationships to Disclose
 
Veronika Bachanova
No Relationships to Disclose
 
James Gerson
No Relationships to Disclose
 
Stefan K. Barta
Honoraria - Mundipharma
Consulting or Advisory Role - Janssen Oncology; Seagen
Research Funding - Bayer (Inst); Celgene; Merck; Seagen; Takeda
Travel, Accommodations, Expenses - Curis
 
Alexey Valeryevich Danilov
Stock and Other Ownership Interests - Abbvie
Honoraria - Dava Oncology; Prime Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Celgene; Curis; Genentech/Roche; Gilead Sciences; Juno Therapeutics; Seagen; Teva; TG Therapeutics; Verastem
Research Funding - Aptose Biosciences; AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech/Roche; Gilead Sciences; Takeda; Verastem
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche
 
Natalie Sophia Grover
Stock and Other Ownership Interests - Sangamo Therapeutics
Consulting or Advisory Role - Seagen; Tessa Therapeutics
Research Funding - Genentech
(OPTIONAL) Uncompensated Relationships - Tessa Therapeutics
 
Narendranath Epperla
Consulting or Advisory Role - Pharmacyclics
Speakers' Bureau - Verastem
 
Madelyn Burkart
No Relationships to Disclose
 
Yazeed Sawalha
No Relationships to Disclose
 
Nilanjan Ghosh
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Juno Therapeutics; Kite, a Gilead company; Seagen; Spectrum Pharmaceuticals; TG Therapeutics
Speakers' Bureau - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen Oncology; Kite/Gilead; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Janssen (Inst); Juno Therapeutics (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst)
 
David Alan Bond
No Relationships to Disclose
 
Kami J. Maddocks
Honoraria - Bayer; Celgene; Novartis; Pharmacyclics; Seagen; Teva
Research Funding - Bristol-Myers Squibb; Merck; Pharmacyclics
 
Talha Badar
No Relationships to Disclose
 
Timothy Fenske
No Relationships to Disclose
 
Jin Guo
No Relationships to Disclose
 
Mary-Kate Malecek
No Relationships to Disclose
 
Peter Martin
Consulting or Advisory Role - Bayer; BeiGene; Celgene; Cellectar; I-Mab; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; MorphoSys; Sandoz; TeneoBio
Research Funding - Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Janssen
 
Jonathon Brett Cohen
Consulting or Advisory Role - Abbvie; Aptitude Medical; AstraZeneca; Celgene; Cellectar; Janssen; Kite/Gilead; Loxo; Seagen
Research Funding - AI Therapeutics (Inst); ASH (Inst); AstraZeneca (Inst); Bioinvent (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen (Inst); Loxo (Inst); Lymphoma Research Foundation (Inst); Novartis (Inst); Takeda (Inst)